Core Insights - Annovis Bio Inc. announced significant efficacy and safety results from its Phase II/III Alzheimer's study of Buntanetap, showing improvements in both APOE4 carriers and non-carriers [1][2][3] Efficacy Findings - Buntanetap demonstrated a statistically significant dose-response in early Alzheimer's patients, with a -3.3 points improvement in ADAS-Cog11 scores over baseline and -2.3 points improvement from placebo [1] - In APOE4 carriers treated with 15mg Buntanetap, there was a -3.15 improvement in ADAS-Cog11 scores [2] Safety Profile - Buntanetap exhibited comparable safety in both APOE4 carriers and non-carriers, with no instances of Amyloid-Related Imaging Abnormalities (ARIA) reported [2][3] - The study included 159 APOE4 carriers (33 homozygotes and 126 heterozygotes) and 159 non-carriers, highlighting the diverse patient population [2] Scientific Context - Recent findings in Nature Medicine have redefined APOE4 homozygosity as a distinct genetic form of Alzheimer's, indicating a need for tailored prevention strategies and treatments [2] - Dr. Samuel Gandy noted the heightened safety risks associated with anti-amyloid drugs for APOE4 homozygotes, contrasting with Buntanetap's safety profile [3] Future Development Plans - Annovis Bio plans to initiate an 18-month Phase III trial focusing on biomarker-positive early Alzheimer's patients to further validate Buntanetap's efficacy and safety [4] - The upcoming investor call will provide detailed findings and outline future development plans for Buntanetap [4] Company Overview - Annovis Bio Inc. is dedicated to developing therapies for neurodegenerative diseases, targeting multiple neurotoxic proteins to restore brain function and improve patient quality of life [5]

MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap. Investor Call Details: Date and Time: June 11, 2024, 4:30pm ET.Register Today ...

Shares of Annovis Bio, Inc. (ANVS) have gained 0.1% over the past four weeks to close the last trading session at $7.29, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $33.50 indicates a potential upside of 359.5%.The average comprises four short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $26.26. While the lowest estimate indicat ...

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases. “This publication is a testament to ...

Core Insights - Annovis Bio, Inc. has published a new article in the journal Biomolecules, focusing on the pharmacokinetic profiles of Posiphen across different species, which consolidates years of research and provides a comprehensive comparison of the drug's behavior in various animal and human samples [1][2]. Group 1: Research Findings - The article presents findings that Posiphen quickly reaches peak concentration in plasma, followed by high absorption in the brain and cerebrospinal fluid (CSF) [2]. - Posiphen metabolizes into two primary metabolites: N1-norposiphen and N8-norposiphen, with both the drug and its metabolites exhibiting rapid clearance in animal models and human subjects, although the drug remains longer in the CSF or brain [2]. - The absorption, distribution, metabolism, and excretion of Posiphen are similar in healthy volunteers and patients with Alzheimer's and Parkinson's diseases [2]. Group 2: Company Overview - Annovis Bio, Inc. is a clinical-stage drug platform company headquartered in Malvern, Pennsylvania, focusing on neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD) [3]. - The company is believed to be the only one developing a drug targeting multiple neurotoxic proteins to restore axonal and synaptic activity, aiming to improve brain function and address memory loss and dementia associated with AD, as well as body and brain dysfunction related to PD [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 ANNOVIS BIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) | --- | --- | --- | |-------|-------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 001-39202 | | | | | | | | | | | | (Commission | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2540421 (State or other jurisdiction of incorporation or organiz ...

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson's disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the Company f ...

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein levels are reduced, consistent with our previous Phase II biomarker dataBased on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying Phase III tr ...

Shares of Annovis Bio, Inc. (ANVS) have gained 0.9% over the past four weeks to close the last trading session at $11.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.40 indicates a potential upside of 198%.The mean estimate comprises five short-term price targets with a standard deviation of $22.13. While the lowest estimate of $13 indicates a 9.4% increase from the curr ...